Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?

Łukasz Kuźbicki; Dariusz Lange; Agata Stanek-Widera; Agnieszka Glińska; Barbara W. Chwirot

doi:10.18632/oncotarget.24825

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?

Łukasz Kuźbicki, Dariusz Lange, Agata Stanek-Widera, Agnieszka Glińska and Barbara W. Chwirot _

PDF | HTML | How to cite

Oncotarget. 2018; 9:17656-17663. https://doi.org/10.18632/oncotarget.24825

Metrics: PDF 1735 views | HTML 1811 views | ?

Abstract

Łukasz Kuźbicki1, Dariusz Lange2, Agata Stanek-Widera2, Agnieszka Glińska1 and Barbara W. Chwirot1

1Department of Medical Biology, Faculty of Biology and Environment Protection, Nicolaus Copernicus University, Toruń, Poland

2Department of Tumor Pathology, Oncology Center – Maria Skłodowska-Curie Institute, Gliwice, Poland

Correspondence to:

Barbara W. Chwirot, email: [email protected]

Keywords: RNF2 (Ring1B); intratumoral expression; immunohistochemistry; prognostic marker; cutaneous melanoma

Received: October 18, 2017 Accepted: February 28, 2018 Published: April 03, 2018

ABSTRACT

Recent studies involving melanoma cell lines suggest that enhanced expression of epigenetic regulator RNF2 supports proliferation and promotes metastasis. However, it is not clear to what extent those data apply to disease progression and prognosis for melanoma patients. Therefore the aim of the present study was to assess the prognostic power of RNF2 intratumoral expression by melanoma cells.

RNF2 was detected immunohistochemically in standard formalin-fixed paraffin-embedded samples of 9 benign nevi, 60 melanomas and 24 nodal metastases.

The lowest percentage of RNF2-positive melanocytes found in nevi was comparable to expression levels in normal skin. The RNF2 expression found in melanomas was significantly higher and it was even more enhanced in metastases. The increased occurrence of RNF2 expressing cells was positively correlated with longer patients’ overall survival. Moreover, a negative correlation was found between intratumoral RNF2 expression and number of generated metastatic lesions.

Our data indicate that development of melanoma is associated with significant changes in RNF2 intratumoral expression and imply that at least for some patients the enhancement of the expression levels of RNF2 in both primary and metastatic lesions may be considered a favorable prognostic factor in melanoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24825

Publication Alerts

Research Papers:

Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?

Abstract